<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704947</url>
  </required_header>
  <id_info>
    <org_study_id>osteoprosis</org_study_id>
    <nct_id>NCT04704947</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis</brief_title>
  <official_title>Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study evaluating selective or nonselective beta blockers use and fracture risk in&#xD;
      patients with primary osteoporosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical study evaluating selective or nonselective beta blockers use and if there is&#xD;
      fracture risk in patients with primary osteoporosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with fracture in each group</measure>
    <time_frame>1 year</time_frame>
    <description>the exact number of patients with fracture in each group</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Beta Blocker Toxicity</condition>
  <arm_group>
    <arm_group_label>nonselective beta blocker group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cardio-selective beta blocker group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty patients with osteoporosis and hypertension on the same treatment as control group in addition to bisoprolol (Concor®) 5 mg once daily titrated as patient's response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ten patient with osteoporosis on alendronate sodium 70 mg (Fosamax®) once/week, vitamin D3 1 mcg once daily and calcium supplement 500 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nonselective beta blocker</intervention_name>
    <description>nonselective beta blocker</description>
    <arm_group_label>nonselective beta blocker group</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cardio-selective beta blocker group</intervention_name>
    <description>cardio-selective beta blocker group</description>
    <arm_group_label>cardio-selective beta blocker group</arm_group_label>
    <other_name>concor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate sodium</intervention_name>
    <description>alendronate sodium</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>cardio-selective beta blocker group</arm_group_label>
    <arm_group_label>nonselective beta blocker group</arm_group_label>
    <other_name>alendronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Male &amp; female osteoporotic patient aged ≥ 50 years&#xD;
&#xD;
               -  Hypertensive &amp; normotensive patients&#xD;
&#xD;
               -  BMD T-score ≥ 2.5 or more SD below peak bone mass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on drugs that may improve osteoporosis disease state such as:&#xD;
&#xD;
               -  Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers&#xD;
                  (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.&#xD;
&#xD;
        Patients on drugs that may worsen osteoporosis disease state such as:&#xD;
&#xD;
        • Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors,&#xD;
        Thyroid replacement therapy and Proton pump inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Abd El-Rafea Abdo, PH D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, ass. prof.</last_name>
    <phone>00201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <zip>35127</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sherief abd-elsalam, ass. prof</last_name>
      <phone>00201147773440</phone>
      <email>sheriefabdelsalam@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Ass. Prof. Tropical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Adrenergic beta-1 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

